Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Anushka Dutta

The Bull Case for Zoetis Stock as Michael Burry Doubles Down

Animal healthcare company Zoetis (ZTS) faces headwinds from companion animal product sales due to a competitive landscape, primarily from its key dermatology franchise and Simparica Trio. Moreover, Zoetis’ Convenia and Cerenia brands face heightened competition from generic brands.

The company is also dealing with lower sales from Librela, its monoclonal antibody (mAb) product for osteoarthritis (OA) pain in pets, due to some safety concerns regarding its usage. Solensia, another one of its OA medicines, has also come under fire. However, Librela has received the vote of confidence from the Veterinary Medicines Directorate in the U.K.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.